Later, β3-AR antagonism reduced melanoma growth in vivo by increasing the NK and CD8 cell numbers as well as their cytotoxicity in the TME through the regulation of Treg and MDSC sub-populations [156]. This evidence concerns the gene CD8A and melanoma.